Form 4: Pacira CMO Reports Routine Tax-Related Share Disposition
Insider Transaction Report
Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, reported the disposition of 381 common shares to cover tax withholding obligations related to a restricted stock unit award.
Summary
- Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, Inc. (PCRX), reported a transaction on January 2, 2026.
- This transaction involved the disposition of 381 shares of common stock at a price of $24.46 per share.
- The shares were withheld by the issuer to cover tax withholding obligations upon the vesting of a restricted stock unit award.
- Following this transaction, Mr. Slonin beneficially owns 178,523.175 shares of common stock directly.
- This total includes 537.166 shares of common stock acquired under the issuer's employee stock purchase plan in December 2025.
Sentiment
Score: 5
Explanation: The filing reports a routine, non-discretionary insider transaction (tax withholding) and an employee stock purchase plan acquisition, which are neutral events in terms of company sentiment.
Positives
- The reporting person acquired 537.166 shares of common stock through the company's employee stock purchase plan in December 2025, indicating continued participation and investment in the company.
Negatives
- The disposition of 381 shares, while for tax purposes, reduces the direct beneficial ownership of the Chief Medical Officer.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This Form 4 filing reports a routine insider transaction, specifically a tax-related disposition of shares, which is a common occurrence for executives receiving equity compensation. It does not provide information directly related to broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Minimal impact as this is a routine, non-discretionary transaction by an executive, not indicative of a change in company fundamentals or management's discretionary view of the stock.
Key Dates
| Date | Description |
|---|---|
| 2025-12 | Acquisition of 537.166 shares of common stock under the issuer's employee stock purchase plan. |
| 2026-01-02 | Transaction date for the disposition of 381 shares to cover tax withholding obligations. |
| 2026-01-06 | Date of signature for the Form 4 filing. |
Keywords
Pacira BioSciences, PCRX, Jonathan Slonin, Chief Medical Officer, Form 4, Insider Transaction, Stock Award, Tax Withholding, Employee Stock Purchase Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.